Breaking News
December 16, 2018 - ‘Easy Way Out’? Stigma May Keep Many From Weight Loss Surgery
December 16, 2018 - Gout drug may protect against chronic kidney disease
December 16, 2018 - Talking about memories enhances the wellbeing of older and younger people
December 16, 2018 - Occupational exposure to pesticides increases risk for cardiovascular disease among Latinos
December 16, 2018 - A biomarker in the brain’s circulation system may be Alzheimer’s earliest warning
December 16, 2018 - Magnesium may play important role in optimizing vitamin D levels, study shows
December 16, 2018 - The effect of probiotics on intestinal flora of premature babies
December 16, 2018 - Parents spend more time talking with kids about mechanics of using mobile devices
December 16, 2018 - Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study
December 16, 2018 - Arterial stiffness may predict dementia risk
December 16, 2018 - Study explores link between work stress and increased cancer risk
December 16, 2018 - Sex work criminalization linked to incidences of violence finds study
December 16, 2018 - Johns Hopkins researchers discover swarming behavior in fish-dwelling parasite
December 16, 2018 - Schistosomiasis prevention and treatment could help control HIV
December 16, 2018 - Early postpartum opioids linked with persistent usage
December 16, 2018 - Johns Hopkins researchers identify molecular causes of necrotizing enterocolitis in preemies
December 16, 2018 - Advanced illumination expands capabilities of light-sheet microscopy
December 16, 2018 - Alzheimer’s could possibly be spread via contaminated neurosurgery
December 16, 2018 - Unraveling the complexity of cancer biology can prompt new avenues for drug development
December 16, 2018 - Inflammatory Bowel Disease, Prostate Cancer Linked
December 16, 2018 - Cannabis youth prevention strategy should target mental wellbeing
December 15, 2018 - Recent developments and challenges in hMAT inhibitors
December 15, 2018 - Sewage bacteria found lurking in Hudson River sediments
December 15, 2018 - CDC selects UMass Amherst biostatistician model that helps predict influenza outbreaks
December 15, 2018 - Researchers reveal brain mechanism that drives itch-evoked scratching behavior
December 15, 2018 - New computer model helps predict course of the disease in prostate cancer patients
December 15, 2018 - Obesity to Blame for Almost 1 in 25 Cancers Worldwide
December 15, 2018 - How the brain tells you to scratch that itch
December 15, 2018 - New findings could help develop new immunotherapies against cancer
December 15, 2018 - World’s largest AI-powered medical research network launched by OWKIN
December 15, 2018 - Young people suffering chronic pain battle isolation and stigma as they struggle to forge their identities
December 15, 2018 - Lifespan extension at low temperatures depends on individual’s genes, study shows
December 15, 2018 - New ingestible capsule can be controlled using Bluetooth wireless technology
December 15, 2018 - Researchers uncover microRNAs involved in the control of social behavior
December 15, 2018 - Research offers hope for patients with serious bone marrow cancer
December 15, 2018 - Link between poverty and obesity is only about 30 years old, study shows
December 15, 2018 - Mass spectrometry throws light on old case of intentional heavy metal poisoning
December 15, 2018 - BeyondSpring Announces Phase 3 Study 105 of its Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Meets Primary Endpoint at Interim Analysis
December 15, 2018 - Study finds that in treating obesity, one size does not fit all
December 15, 2018 - Tenacity and flexibility help maintain psychological well-being, mobility in older people
December 15, 2018 - Study reveals role of brain mechanism in memory recall
December 15, 2018 - High levels of oxygen encourage the brain to remain in deep, restorative sleep
December 15, 2018 - Experimental HIV vaccine strategy works in non-human primates, research shows
December 15, 2018 - Genetically modified pigs could limit replication of classical swine fever virus, study shows
December 15, 2018 - FDA Approves Herzuma (trastuzumab-pkrb), a Biosimilar to Herceptin
December 15, 2018 - Cost and weight-loss potential matter most to bariatric surgery patients
December 15, 2018 - Cancer Research UK and AstraZeneca open new Functional Genomics Centre
December 15, 2018 - New research lays out potential path for treatment of Huntington’s disease
December 15, 2018 - Prestigious R&D 100 Award presented to Leica Microsystems
December 15, 2018 - Study shows septin proteins detect and kill gut pathogen, Shigella
December 15, 2018 - Study sheds new light on disease-spreading mosquitoes
December 15, 2018 - 2017 Saw Slowing in National Health Care Spending
December 15, 2018 - Monitoring movement reflects efficacy of mandibular splint
December 15, 2018 - Study supports BMI as useful tool for assessing obesity and health
December 15, 2018 - Self-guided, internet-based therapy platforms effectively reduce depression
December 15, 2018 - Organically farmed food has bigger climate impact than conventional food production
December 15, 2018 - Faster, cheaper test has potential to enhance prostate cancer evaluation
December 15, 2018 - Researchers study abnormal blood glucose levels of patients after hospital discharge
December 15, 2018 - Swedish scientists explore direct association of dementia and ischemic stroke deaths
December 15, 2018 - Study finds 117% increase in number of dementia sufferers in 26 years
December 15, 2018 - Eczema Can Drive People to Thoughts of Suicide: Study
December 15, 2018 - Link between neonatal vitamin D deficiency and schizophrenia confirmed
December 15, 2018 - Nurse denied life insurance because she carries naloxone
December 15, 2018 - Ritalin drug affects organization of pathways that build brain networks used in attention, learning
December 15, 2018 - Research pinpoints two proteins involved in creation of stem cells
December 15, 2018 - Gut bacteria may modify effectiveness of anti-diabetes drugs
December 15, 2018 - A new type of ‘painless’ adhesive for biomedical applications
December 15, 2018 - Early physical therapy associated with reduction in opioid use
December 15, 2018 - Breast cancer protection from pregnancy begins many decades later, study finds
December 15, 2018 - How often pregnant women follow food avoidance strategy to prevent allergy in offspring?
December 15, 2018 - Using machine learning to predict risk of developing life-threatening infections
December 15, 2018 - How imaginary friends could boost children’s development
December 15, 2018 - Folate deficiency creates more damaging chromosomal abnormalities than previously known
December 15, 2018 - Study provides new insights into molecular mechanisms underlying role of amyloid in Alzheimer’s disease
December 15, 2018 - For the asking, a check is in the mail to help pay for costly drugs
December 15, 2018 - UA scientists uncover biological processes leading to rare brain disorder in babies
December 15, 2018 - The largest database on industrial poisons
December 15, 2018 - ESMO Immuno-Oncology Congress showcases novel technologies set to benefit many cancer patients
December 15, 2018 - Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome
December 15, 2018 - Left ventricular noncompaction – Genetics Home Reference
New Drugs on Horizon for Atopic Dermatitis

New Drugs on Horizon for Atopic Dermatitis

image_pdfDownload PDFimage_print

The evolution in the understanding of the pathogenesis of atopic dermatitis has fueled drug discovery in this arena.

Both T helper cell type 2 (TH2) lymphocyte-driven inflammation, and inflammatory mediators, have become specific targets for anti-inflammatory therapy, according to Lawrence Eichenfield, MD, a professor of dermatology and pediatrics at the University of California San Diego.

Eichenfield, co-author of a comprehensive article in Clinics in Dermatology on current and emerging topical agents for atopic dermatitis (AD), noted that for early intervention, several small studies have demonstrated that emollients decrease the rate of infants at risk for developing AD. Larger studies are underway, he said.

For established AD, rather than solely focusing on managing flares and treatment of acute disease, “we are starting to emphasize long-term disease control,” Eichenfield said. “Strategies to use topical agents in long-term models have a good evidence basis with either topical corticosteroids, which are generally used two to three times a week, or topical calcineurin inhibitors, which may be used intermittently.”

The goal of such a model is to create topical regimens that will minimize the signs and symptoms of disease, while delivering agents as safely as possible. “This mimics the model for control of asthma, which is not based on simply treating active wheezing, but incorporating a variety of medications to minimize the disease over long periods of time,” Eichenfield said.

In December 2016, crisaborole ointment 2% (Eucrisa) received FDA approval for the treatment of AD, making it “the first new novel agent since 2001,” according to Eichenfield. The phosphodiesterase (PDE)-4 inhibitor agent “is neither a topical corticosteroid nor a topical calcineurin inhibitor. It targets an inflammatory mediator and has been shown to work topically to decrease signs and symptoms of AD.”

Because crisaborole is not a corticosteroid, “there is no atrophy, telangiectasia, or hypopigmentation attributed to the drug’s use,” Eichenfield said.

Crisaborole was approved to treat mild to moderate eczema in pediatric (ages ≥2 years) and adult patients. It works by inhibiting phosphodiesterase 4 (PDE-4).

Eichenfield said he was pleased that crisaborole has been added to his armamentarium of AD therapy, either as monotherapy or along with other topical steroids. “We are using it most commonly in long-term care regimens to minimize patient exposure to topical corticosteroids,” he said.

Furthermore, the absence of limitation of duration of use “is highly valuable.” In his practice, crisaborole has been effective in controlling symptoms in his patients in which no significant adverse effects have been observed, he said.

There are currently other topical PDE-4 agents in development for AD along with agents that target janus kinase inhibitors. “The janus kinase pathway is one that apparently can be very important in mediating the inflammation of AD,” explained Eichenfield.

Currently, there are two approved oral janus inhibitors for non-dermatologic indications: Myelodysplasia and rheumatoid arthritis (RA). One of these inhibitors, tofacitinib (Xeljanz) for RA, “has also been studied for AD [but] that drug is not being actively developed at the present time,” Eichenfield said. “But there are many other janus inhibitors that are in clinical studies for AD.”

Eichenfield said the development of new topical therapies for AD is happening concurrently with the development and early use of both, along with other small molecular agents for systemic therapy.

“It is hoped that the heightened awareness about the disease will bring patients into the dermatologist to allow us to improve their AD and minimize the disease process,” Eichenfield said.

This article originally appeared on our partner’s website Dermatology Times, which is a part of UBM Medica. (Free registration is required.)

Eichenfield disclosed relevant relationships with Anacor (Pfizer), Medimetriks, and Roivant Sciences.

2017-12-09T14:00:00-0500

Tagged with:

About author

Related Articles